Developer of immunomodulatory therapeutics designed for the treatment of acute inflammatory and rare diseases. ReAlta Life Sciences is based in Norfolk, VA. It was valued at $230 million at its later-stage round in Apr 2026, the last priced event on record. It has raised $155 million across 5 recorded rounds; the latest was a $25 million early-stage round in Dec 2024.
PMV mark · valuation
$230.0M
Oct 2026
Priced at
its later-stage round
Apr 2026
Total raised
$155.4M
Last round
Early Stage VC
Dec 2024
Cap table — not yet on record
ReAlta Life Sciences's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of ReAlta Life Sciences with a free account
·The complete investor list: 12 names
·Watch ReAlta Life Sciences: the Monday email on marks, rounds and moves
Where does ReAlta Life Sciences's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across ReAlta Life Sciences's 5 recorded funding rounds.
